Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Absolute 10-year risk of dementia by age, sex and APOE genotype: a population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden adn prothrombin mutations and blook type

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. RE: Time to stop mammography screening?

    Research output: Contribution to journalJournal articleResearch

  1. General health checks in adults for reducing morbidity and mortality from disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias

    Research output: Contribution to journalReviewResearchpeer-review

  3. Challenges of independent assessment of potential harms of HPV vaccines

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The European Medicines Agency makes clinical study reports publicly available and publishes reasons for not approving applications for marketing authorization. Duloxetine has been approved in Europe for the treatment of stress urinary incontinence in women. The reported adverse effects of duloxetine include mental health problems and suicidality. We obtained clinical study reports from the European Medicines Agency concerning use of this drug for stress urinary incontinence.

METHODS: We performed a meta-analysis of 4 randomized placebo-controlled trials of duloxetine (involving a total of 1913 patients) submitted to the European Medicines Agency for marketing approval for the indication of stress urinary incontinence in women. We used data from the clinical study reports (totalling 6870 pages and including individual patient data) to assess benefits (including frequency of incontinence and changes in quality-of-life scores, such as Patient Global Impression of Improvement rating) and harms (both general harms, including discontinuation because of adverse events, and harms related to suicidality, violent behaviour and their potential precursors, such as akathisia and activation [stimulating effects such as insomnia, anxiety and agitation]).

RESULTS: Duloxetine was significantly better than placebo in terms of percentage change in weekly incontinence episodes (mean difference -13.56%, 95% confidence interval [CI] -21.59% to -5.53%) and change in Incontinence Quality of Life total score (mean difference 3.24, 95% CI 2.00 to 4.48). However, the effect sizes were small, and a sensitivity analysis (with removal of one trial) showed that the number needed to treat for a Patient Global Impression of Improvement rating of "much better or very much better" was 8 (95% CI 6 to 13). The numbers needed to harm were 7 (95% CI 6 to 8) for discontinuing because of an adverse event and 7 (95% CI 6 to 9) for experiencing an activation event. No suicidality, violence or akathisia events were noted.

INTERPRETATION: Although duloxetine is effective for stress urinary incontinence in women, the rates of associated harm were high when individual patient data were analyzed, and the harms outweighed the benefits.

Original languageEnglish
JournalCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
Volume189
Issue number5
Pages (from-to)E194-E203
ISSN0008-4409
DOIs
Publication statusPublished - 6 Feb 2017

    Research areas

  • Affective Symptoms, Akathisia, Drug-Induced, Antidepressive Agents, Anxiety, Duloxetine Hydrochloride, Female, Humans, Mental Disorders, Psychoses, Substance-Induced, Randomized Controlled Trials as Topic, Risk Assessment, Sleep Initiation and Maintenance Disorders, Suicidal Ideation, Treatment Outcome, Urinary Incontinence, Stress, Violence, Journal Article, Meta-Analysis

ID: 52618095